What do the numbers say about Sanofi India (SANOFI)? Here's a look at its financials, valuation, and ownership data.
Sanofi India Revenue Trend
Top-line pressure showed for Sanofi India, with revenue declining 30.4% to ₹2,030 Cr in FY2024.
Stepping back, Sanofi India's 0.3% revenue CAGR over 10 years is tepid, barely outpacing inflation.
Sanofi India is a mid-sized pharmaceuticals company by revenue, with a top line of ₹2,030 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2024 | ₹2,030 Cr | -30.4% |
| FY2023 | ₹2,916 Cr | +2.6% |
| FY2022 | ₹2,842 Cr | -6.2% |
| FY2021 | ₹3,031 Cr | +1.3% |
| FY2020 | ₹2,992 Cr | — |
View Sanofi India's full 10-year revenue trend with CAGR analysis →
Sanofi India Profitability
The bottom line took a hit: Sanofi India's net profit slipped 31.4% to ₹413 Cr in FY2024.
Net profit margin held relatively steady at 20.4% in FY2024.
On an EPS basis, the company earned ₹179.46 (diluted) in FY2024 versus ₹261.78 in FY2023.
Is Sanofi India Undervalued
Per the P/E Ratio model, Sanofi India has an estimated intrinsic value of ₹4,640 (44.4% upside).
Sanofi India shares are currently trading at ₹3,212.90.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹4,640 | 44.4% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Sanofi India with detailed assumptions →
Sanofi India Shareholding Pattern
At 60.4%, the promoter stake has been flat for the past 4 quarters.
FII ownership stands at 5.6%, up from the 5.6% recorded a year ago.
Domestic institutions moved their stake down to 21.1% from 23.1% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 60.4% | 5.6% | 21.1% | 12.8% |
| Dec 2025 | 60.4% | 5.5% | 21.3% | 12.7% |
| Sep 2025 | 60.4% | 5.6% | 22.3% | 11.8% |
| Jun 2025 | 60.4% | 5.6% | 23.1% | 10.9% |
Track quarterly shareholding changes for Sanofi India →
Sanofi India Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹16.12B at the end of FY2024, down 6.0% from ₹17.15B a year earlier.
Inventories is the largest block at 31.0%, followed by Other Assets at 19.4% and Cash & ST Investments at 18.3%.
Equity makes up 53.4% of liabilities and equity, with debt at 1.2% and operating liabilities at 45.4%. Over the year, debt is up 1.6% and equity is down 15.2%.
Balance sheet composition — FY 2024
| Category | Value |
|---|---|
| Cash & ST Investments | 2.95B |
| Receivables | 2.30B |
| Inventories | 5.00B |
| Property, Plant & Equipment | 2.74B |
| Intangibles & Goodwill | 13.00M |
| Other Assets | 3.12B |
| Category | Value |
|---|---|
| Equity | 8.61B |
| Short-term Debt | 53.00M |
| Long-term Debt | 140.00M |
| Trade Payables | 4.06B |
| Other Liabilities | 3.26B |
Sanofi India Key Highlights
Here's the bottom line on Sanofi India (SANOFI) based on the latest available financials.
Revenue of ₹2,030 Cr in FY2024, down 30.4% year-over-year.
Long-term revenue has been compounding at 0.3% annually over 10 years.
The company is profitable, with a net margin of 20.4% and net income of ₹413 Cr.
The P/E Ratio model implies 44.4% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Sanofi India.